M Rushton1, C Johnson2, S Dent1. 1. The Ottawa Hospital Cancer Centre, and. 2. Department of Medicine, Division of Cardiology, The Ottawa Hospital, Ottawa, ON.
Abstract
BACKGROUND: Trastuzumab has improved survival for women with her2-positive breast cancer, but its use is associated with an increased risk of cardiotoxicity. With increased survivorship, the long-term effects of cancer treatment are an important consideration for clinicians and patients. We reviewed the current literature on predicting trastuzumab-related cardiotoxicity and tested a clinical risk score (crs) in a real-world breast cancer population to assess its utility in predicting permanent cardiotoxicity. METHODS: In this retrospective exploratory cohort study of breast cancer patients referred to a cardio-oncology clinic at a tertiary care centre between October 2008 and August 2014, a crs was calculated for each patient, and a sensitivity analysis was performed. RESULTS: Of the 143 patients included in the study, 62 (43%) experienced a cardiac event, and of those 62 patients, 43 (69%) experienced full recovery of cardiac function. In applying the crs, 119 patients (83%) would be considered at low risk, 14 (10%) at moderate risk, and 10 (7%) at high risk to develop heart failure or cardiomyopathy. When applied to the study population, the high-risk cut-off score had a sensitivity of 0.13 [95% confidence interval (ci): 0.08 to 0.20] and a specificity of 0.94 (95% ci: 0.87 to 0.97). The positive predictive value was 0.07 (95% ci: 0.03 to 0.13), and the negative predictive value was 0.93 (95% ci: 0.87 to 0.96). CONCLUSIONS: The crs demonstrated good specificity and negative predictive value for the development of permanent cardiotoxicity in a real-world population of breast cancer patients, suggesting that intensive cardiac monitoring might not be warranted in low-risk patients, but that high-risk patients might benefit from early referral to cardio-oncology for optimization. Further study using the crs in a larger breast cancer population is warranted to identify patients at low risk of long-term trastuzumab-related cardiotoxicity.
BACKGROUND:Trastuzumab has improved survival for women with her2-positive breast cancer, but its use is associated with an increased risk of cardiotoxicity. With increased survivorship, the long-term effects of cancer treatment are an important consideration for clinicians and patients. We reviewed the current literature on predicting trastuzumab-related cardiotoxicity and tested a clinical risk score (crs) in a real-world breast cancer population to assess its utility in predicting permanent cardiotoxicity. METHODS: In this retrospective exploratory cohort study of breast cancerpatients referred to a cardio-oncology clinic at a tertiary care centre between October 2008 and August 2014, a crs was calculated for each patient, and a sensitivity analysis was performed. RESULTS: Of the 143 patients included in the study, 62 (43%) experienced a cardiac event, and of those 62 patients, 43 (69%) experienced full recovery of cardiac function. In applying the crs, 119 patients (83%) would be considered at low risk, 14 (10%) at moderate risk, and 10 (7%) at high risk to develop heart failure or cardiomyopathy. When applied to the study population, the high-risk cut-off score had a sensitivity of 0.13 [95% confidence interval (ci): 0.08 to 0.20] and a specificity of 0.94 (95% ci: 0.87 to 0.97). The positive predictive value was 0.07 (95% ci: 0.03 to 0.13), and the negative predictive value was 0.93 (95% ci: 0.87 to 0.96). CONCLUSIONS: The crs demonstrated good specificity and negative predictive value for the development of permanent cardiotoxicity in a real-world population of breast cancerpatients, suggesting that intensive cardiac monitoring might not be warranted in low-risk patients, but that high-risk patients might benefit from early referral to cardio-oncology for optimization. Further study using the crs in a larger breast cancer population is warranted to identify patients at low risk of long-term trastuzumab-related cardiotoxicity.
Entities:
Keywords:
Breast cancer; cardiotoxicity; heart failure; trastuzumab
Authors: Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Timothy C Tan; Victor Cohen; Jose Banchs; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie Journal: Circ Cardiovasc Imaging Date: 2012-06-28 Impact factor: 7.792
Authors: Lee W Jones; Kerry S Courneya; John R Mackey; Hyman B Muss; Edith N Pituskin; Jessica M Scott; Whitney E Hornsby; April D Coan; James E Herndon; Pamela S Douglas; Mark Haykowsky Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544
Authors: Felipe Ades; Dimitrios Zardavas; Ana Catarina Pinto; Carmen Criscitiello; Philippe Aftimos; Evandro de Azambuja Journal: Breast Date: 2014-05-01 Impact factor: 4.380
Authors: James R Cerhan; Steven C Moore; Eric J Jacobs; Cari M Kitahara; Philip S Rosenberg; Hans-Olov Adami; Jon O Ebbert; Dallas R English; Susan M Gapstur; Graham G Giles; Pamela L Horn-Ross; Yikyung Park; Alpa V Patel; Kim Robien; Elisabete Weiderpass; Walter C Willett; Alicja Wolk; Anne Zeleniuch-Jacquotte; Patricia Hartge; Leslie Bernstein; Amy Berrington de Gonzalez Journal: Mayo Clin Proc Date: 2014-03 Impact factor: 7.616
Authors: Edward H Romond; Jong-Hyeon Jeong; Priya Rastogi; Sandra M Swain; Charles E Geyer; Michael S Ewer; Vikas Rathi; Louis Fehrenbacher; Adam Brufsky; Catherine A Azar; Patrick J Flynn; John L Zapas; Jonathan Polikoff; Howard M Gross; David D Biggs; James N Atkins; Elizabeth Tan-Chiu; Ping Zheng; Greg Yothers; Eleftherios P Mamounas; Norman Wolmark Journal: J Clin Oncol Date: 2012-09-17 Impact factor: 44.544
Authors: Michael A Biersmith; Matthew S Tong; Avirup Guha; Orlando P Simonetti; Daniel Addison Journal: J Am Heart Assoc Date: 2020-01-21 Impact factor: 5.501
Authors: Susan Dent; Dean Fergusson; Olexiy Aseyev; Carol Stober; Gregory Pond; Arif A Awan; Sharon F McGee; Terry L Ng; Demetrios Simos; Lisa Vandermeer; Deanna Saunders; John F Hilton; Brian Hutton; Mark Clemons Journal: Curr Oncol Date: 2021-12-03 Impact factor: 3.677